Icon
+91 94997 68112
Login Register

Lenvima - (Eq 4, 10 mg; capsule, oral)

Lenvatinib mesylate EISAI INC
Eq 4, 10 mg; capsule, oral
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
Yes
****** ******** ** ***. ****** ******** ***** * **** ** ** ****** ******** (*** **, ****) *** *** *********. ** ****** **** *** ****** ******** **** ****** ** *** ****. ******** ****** **** ****** ** **** ****. *****, *** ****** (******) ** ********* **** ******* ******** (*** **, ****) *** ******** (*** **, ****)
Lenvima Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
****** ******** *** ********* *** ********* **** ** **** *, **** ******** *** ** *** ****** ************/ ******** ********* ******* ****** ************/ ******** ********* ******* *** ********* (***** ******)
*** ****** **** *** *** ********* ****** *** ******** *** ** *** (***** ******) ******* (***** ******) ******* (***** ******) *** ********* (***** ******)
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** ******** *** \ ********* *** *, **** ******* **** ******* *** **** *** *** ****
*** ****** *** \ ********* -**- ******* ********* ******** ******* *** **** *** *** ****
  1. *** **, **** : ****** ******** ******** ***** ***** **'* **** ** ****** ** ****** ******** (*** **, ****)
  2. *** **, **** : *** ****** ******** ***** ***** **'* **** ** ****** ** ****** ******** (*** **, ****) *** ******** (*** **, ****)
  3. *** *, **** : ***** ***** * **** ******* ****** ******** ** ****** ******** (*** **, ****)
  4. *** **, **** : ***** ***** * **** ******* *** ****** ** ******* ******** (*** **, ****) *** ******** (*** **, ****)
  5. *** *, **** : ***** ***** ** ******* ********* ******* ****** ******** ** ******* '*** *** '***.
  6. *** *, **** : ***** ***** * **** ******* ****** ******** ** ****** '***.
  7. *** **, **** : ***** ******* **** ********* **** ****** ** *** *** ** ****** **. *** (******** *** ** ***)
  8. *** **, **** : ***** ******* **** ********* **** *** ****** ** *** *** ** ****** **. *** (******** *** ** ***)
  9. *** **, **** : ***** **** *** ****** *** ****** ******** **** ************ ** ***** ****** ****** '*** (*** **, ****)
  10. *** **, **** : ***** *** *** ****** ********** *** ****** **** *** ********* ******* '*** *** '***. *** ******** ********* ******* *******.
  11. *** **, **** : ***** *** ****** ********** *** ****** **** ****** ********* ******* '*** *** '***. *** ******** ********* ******* *******.
  12. *** **, **** : ***** *** *** ****** **** ******* ********** **** ************ ** ****** ** ' *** *** '***.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.